Overdose. Taking too much of one or more medications may lead to respiratory arrest and death.
Overdose. You can die from an overdose of opioid medications. The risk of dangerous overdose is higher if you take opioids combined with alcohol or other medications that can make you sleepy (See Appendix I). Most overdoses are unintentional and can happen to anyone taking opioid medication.
Overdose. Unintentional overdose of prescription opioids as well as non-prescribed opioids such as heroin can lead to death. Having multiple opioid prescriptions from different prescribers (doctor shopping) also increases the likelihood of overdose. It is important to know about naloxone (often referred to by the brand name Narcan®), which reverses opioid overdose. Naloxone can be prescribed by your provider and in Massachusetts it is also available without a prescription at retail pharmacies. While there is information to educate you, your family, and close friends on how to use it, we encourage you to talk to your treating provider to learn more and be educated on how to use it. Patient-Centered Zero Tolerance Policy for Inpatient Opioid Misuse Because we care about your wellbeing and are committed to providing excellent care, we enforce a zero tolerance policy for misuse of prescribed and non-prescribed opioids misuse within our institution. In order to provide safe and high-quality care, we screen patients for opioid dependence, misuse, and/or addiction. Our focus is to treat you with respect in a non-judgmental manner. It is important that you work with your treating provider to share information regarding your use of opioids and/or other drugs, including alcohol and street drugs. Your previous history of drug use and family history are very important to developing your treatment plan. A witnessed urine or blood drug screening may also be requested at any time to further help us in our treatment plan for you. We may also ask that you permit us to search you and your belongings. We may also ask your visitors to be searched as well as their belongings, when the need for this arises. We ask that you comply with us throughout this process. Our goal is to work with you to treat your addiction to opioids or other substances, and to assist you on the journey to recovery. Prohibited items pose a safety risk to you and/or others and include, but are not limited to: drug paraphernalia; prescribed drugs, including opioids; use of alcohol; and controlled substances, including heroin. For your safety and that of other patients and our staff, we will remove all prohibited substances if discovered. Family and Visitors A patient’s family and visitors can play a major role in the treatment and recovery of their loved ones. We invite family members, designated patient representatives, caregivers, and visitors to read this policy and to learn about addiction and why it matters to...
Overdose. Overdose by the patient, or other people who have access to these medications, may impair breathing, and lead to coma or death.
Overdose. This refers to the administration of a quantity of a medicinal product given per administration or cumulatively, which is above the maximum recommended dose according to the authorized product information. Patient Support Programme A patient support programme is an organisedorganized system where a marketing authorisationauthorization holder receives and collects information relating to the use of its medicinal products. Examples are post-authorisationauthorization patient support and disease management programmes, surveys of patients and healthcare providers, information gathering on patient compliance, or compensation/re-imbursement schemes.
Overdose. To date, no cases of overdosage with budesonide are known. In view of the properties of budesonide contained in Budenofalk 3 mg, an overdose resulting in toxic damage is extremely unlikely.
Overdose. A dose taken (accidentally or intentionally) exceeding the dose as prescribed by the protocol or the maximal recommended daily dose as stated in the Product Labelling, (as it applies to the daily dose for the subject/patient in question). The Parties agree that in the course of conducting a Clinical Study, the terms of the Clinical Study Protocol (as fully approved by all applicable bodies) override the local Product Labelling.
Overdose. An overdose is a deliberate or accidental administration of any study treatment to a study patient, at a dose greater than that which was assigned to that patient per the study protocol. If an overdose occurs, the Investigator and Karyopharm should be notified immediately, and the patient should be observed closely for AEs. Resulting symptoms should be treated, as appropriate, and the incident of overdose and related AEs and/or treatment should be documented in the patient’s medical record and in the eCRF. Information regarding the overdose is to be recorded on an SAE report form and sent to Karyopharm Pharmacovigilance, regardless of whether or not an AE or SAE has occurred due to the overdose. If the overdose is associated with an SAE, the SAE report form must be submitted to Karyopharm Pharmacovigilance within 24 hours of awareness. If there is no AE or SAE, the report must be submitted as soon as possible. Doses of selinexor of up to 160 mg per week (80 mg twice weekly, the approved dose in RRMM) and weekly doses of up to 100 mg have been given to patients with advanced cancers with adequate tolerability. No specific antidotes for overdose are known at this time.
Overdose. An overdose is a deliberate or accidental administration of any study treatment to a study patient, at a dose greater than that which was assigned to that patient per the study protocol. If an overdose occurs, the Investigator and then Sponsor should be notified immediately, and the patient should be observed closely for AEs. Resulting symptoms should be treated, as appropriate, and the incident of overdose and related AEs and/or treatment should be documented in the patient’s medical record and in the eCRF. Information regarding the overdose is to be recorded on an SAE Report Form and sent to Karyopharm Pharmacovigilance Department at xxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx, regardless of whether or not an AE or SAE has occurred due to the overdose. If the overdose is associated with an SAE, the SAE Report Form must be submitted to Karyopharm Pharmacovigilance within 24 hours of awareness. If there is no AE or SAE, the report must be submitted as soon as possible.
Overdose. An overdose is defined as administration of a dose that is over 50 mg/kg. An overdose is not an AE. An overdose will be reported even if it does not result in an AE. An overdose will be recorded in the source documents and reported to the Sponsor or designee within 24 hours.
